N/A
N=204
The Detection Of Circulating Tumor Cells (CTC) In Patients With NSCLC Undergoing Definitive Radiotherapy Or Chemoradiotherapy
Non-small Cell Lung Cancer
Bottom Line
View on ClinicalTrials.gov: NCT02135679 ↗Enrolled (actual)
204
Serious AEs
—
Results posted
Oct 2024
Primary outcome: Primary: To Describe the Pattern of CTCs Before and After Definitive Radiotherapy for Each Treatment Stratum — 3.9; 9.1; 9.1; 9.1 CTCs/mL
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Radiotherapy (Radiation)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Abramson Cancer Center at Penn Medicine
- Primary completion
- Dec 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY To Describe the Pattern of CTCs Before and After Definitive Radiotherapy for Each Treatment Stratum |
3.9; 9.1; 9.1; 9.1; 3.9; 0.4 | — |
Summary
CTC levels collected pre-surgery will be correlated with pathological samples.
Eligibility Criteria
Inclusion Criteria
- Patients with biopsy-proven NSCLC who are undergoing definitive radiotherapy as a part of their treatment regimen.
- Age 18 or older
- Signed informed consent
- Patients who are incapable of providing informed consent are excluded from participating in this study.
Data sourced from ClinicalTrials.gov (NCT02135679). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.